Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Breast Cancer | Primary research

Efficacy analysis of intraoperative radiotherapy in patients with early-stage breast cancer

Authors: Lin Wang, Minmin Zhu, Yuelong Cui, Xudong Zhang, Guowen Li

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

To analyze the clinical efficacy of intraoperative radiotherapy (IORT) after breast-conserving surgery (BCS) in patients with early-stage breast cancer (BC), and to investigate the relationship between its influencing factors and clinical efficacy and prognosis.

Methods

A total of 73 patients with early-stage BC who underwent IORT after BCS in our hospital were selected in this research.

Results

Kaplan-Meier survival analysis was used to analyze the related factors of BCS and IORT of disease-free survival (DFS) and overall survival (OS). It was found that only age (χ2 = 14.035, P = 0.003) was statistically positively correlated with the patient’s DFS, and local recurrence and metastasis rate and mortality were higher in patients over 70 years old. Log rank test was used to analyze multiple factors. Only the diameter of the applicator (χ2 = 70.378, P < 0.05) was statistically significant with wound complications, and the larger the diameter, the higher incidence of wound complications. The remaining risk factors did not increase the incidence of wound complications. COX multivariate analysis showed that age was an independent risk factor for DFS rate and the risk factor had no significant effect on the OS rate of patients undergoing IORT after BCS.

Conclusions

IORT may be a safe form of treatment for the selected patients with early-stage BC, and can achieve satisfactory esthetic effect. Larger applicator diameters may increase the incidence of wound complications. Age is an independent risk factor for DFS in early-stage BC patients undergoing IORT after BCS.
Literature
1.
Chen WQ, Zheng RS. Incidence, mortality and survival analysis of breast cancer in China. Chin J Clin Oncol. 2015;42:668–74.
2.
Li YH, Zhang LH, Chen X. Research progress of breast-conserving surgery combined with intraoperative radiotherapy for early breast cancer. Chin J Endocr Surg. 2018;12:85–8.
3.
Reintgen C, Reintgen D, Solin LJ. Advances in local regional treatment for patients with early target breast cancer: a review of the field. Clinic Breast Cancer. 2010;10:180–7.CrossRef
4.
Noël G, Mazeron JJ. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Cancer Radiather. 2001;5:92–4.CrossRef
5.
Reitsamer R, Sedlmayer F, Kopp M, Kametriser G, Menzel C, Glueck S, et al. Concepts and techniques of intraoperative radiotherapy (IORT) for breast cancer. Breast Cancer. 2008;15:40–6.CrossRef
6.
Leonardi MC, Maisonneuve P, Mastropasqua MG, Cattani F, Fanetti G, Morra A, et al. Comparison of treatment outcome between invasive lobular and ductal carcinomas in patients receiving partial breast irradiation with intraoperative electrons. Int J Radiat Oncol Biol Phys. 2017;99:173–81. CrossRef
7.
Fastner G, Reitsamer R, Sedlmayer F. Partial breast irradiation with intraoperative electrons versus conventional external whole breast irradiation for early breast cancer. Results of the ELIOT trial. Strahlenther Onkol. 2014;190:422–4.CrossRef
8.
Livi L, Meattini I, Marrazzo L, Simontacchi G, Pallotta S, Saieva C, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015;51:451–63.CrossRef
9.
Yin WB, Gu XZ. Radiation oncology. Beijing: Pecking Union Medical College Press; 2002. p. 1059–87.
10.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16.CrossRef
11.
Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 2017;7:73–9. CrossRef
12.
Wickberg A, Holmberg L, Adami HO, Magnuson A, Villman K, Liljegren G. Sector resection with or without postoperative radiotherapy for stage I breast cancer: 20⁃year results of a randomized trial. J Clin Oncol. 2014;32:791⁃7.
13.
Williams NR, Pigott KH, Brew-Graves C, Keshtgar MR. Intraoperative radiotherapy for breast cancer. Gland Surg. 2014;3:109–19.PubMedPubMedCentral
14.
Holmes DR. Intraoperative radiotherapy in breast conserving surgery. J Surg Oncol. 2014;110:68–74.CrossRef
15.
Wallace M, Ye H, Wobb J, Jawad MS, Dekhne N, Brabbins DS. Accelerated partial-breast irradiation (APBI) versus whole-breast irradiation (WBI) in treatment of the biological subtypes of breast cancer:an analysis of comparative effectiveness. J Clin Oncol. 2015;33:45.
16.
Subhedar P, Olcese C, Patil S, Morrow M, Van Zee KJ. Decreasing recurrence rates for ductal carcinoma in situ: analysis of 2996 women treated with breast⁃conserving surgery over 30 years. Ann Surg Oncol. 2015;22:3273–81.CrossRef
17.
Meattini I, Saieva C, Miccinesi G, Desideri I, Francolini G, Scotti V, et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: health-related quality of life final analysis from the Florence phase 3 trial. Eur J Cancer. 2017;76:17–26.CrossRef
18.
Harat A, Harat M, Makarewicz R. Whole breast irradiation vs. APBI using multicatheter brachytherapy in early breast cancer-simulation of treatment costs based on phase 3 trial data. J Contemp Brachyther. 2016;8:505–11. CrossRef
19.
Lemanski C, Bourgier C, Draghici R, Thezenas S, Morel A, Rouanet P, et al. Intraoperative partial irradiation for highly selected patients with breast cancer: Results of the INTRAOBS prospective study. Cancer Radiother. 2020;24:114–9.CrossRef
20.
Grobmyer SR, Lightsey JL, Bryant CM, Shaw C, Yeung A, Bhandare N, et al. Low-kilovoltage, single-dose intraoperative radiation therapy for breast cancer:resuits and impact on a multidisciplinary breast cancer program. J Am Coll Surg. 2013;216:617–23 (discussion 623-4). CrossRef
21.
Piotrowski I, Kulcenty K, Wichtowski M, Murawa D, Suchorska W. Intraoperative radiotherapy of breast cancer and its biological effects. Breast Care. 2017;12:109–13. CrossRef
22.
Jacobs DHM, Speijer G, Petoukhova AL, Roeloffzen EMA, Straver M, Marinelli A, et al. Acute toxicity of intraoperative radiotherapy and external beam-accelerated partial breast irradiation in elderly breast cancer patients. Breast Cancer Res Treat. 2018;169:549–59.CrossRef
23.
Valente SA, Tendulkar RD, Cherian S, O’Rourke C, Greif JM, Bailey L, et al. TARGIT-R (Retrospective): North American experience with intraoperative radiation using low-kilovoltage X-rays for breast cancer. Ann Surg Oncol. 2016;23:2809–15. CrossRef
24.
Hanna GG, Kirby AM. Intraoperative radiotherapy in early stage breast cancer: potential indications and evidence to date. Br J Radiol. 2015;88:20140686.CrossRef
25.
Zeidan YH, Habib JG, Ameye L, Paesmans M, de Azambuja E, Gelber RD, et al. Postmastectomy radiation therapy in women with T1⁃T2 tumors and 1 to 3 positive lymph nodes: analysis of the breast international group 02⁃98 trial. Int J Radiat Oncol Biol Phys. 2018;101:316–24. CrossRef
26.
Rakhra S, Bethke K, Strauss J, Hayes JP, Hansen N, Khan SA, et al. Risk factors leading to complications in early-stage breast cancer following breast-conserving surgery and intraoperative radiotherapy. Ann Surg Oncol. 2017;24:1258–61. CrossRef
27.
Wenz F, Welzel G, Blank E, Hermann B, Steil V, Sütterlin M, et al. Intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage X-rays: the first 5 years of experience with a novel approach. Int J Radiat Oncol Biol Phys. 2010;77:1309–14.CrossRef
Metadata
Title
Efficacy analysis of intraoperative radiotherapy in patients with early-stage breast cancer
Authors
Lin Wang
Minmin Zhu
Yuelong Cui
Xudong Zhang
Guowen Li
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01533-z

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Review

Ibrutinib in B-cell lymphoma: single fighter might be enough?

Primary research

Genomic profiling of colorectal cancer with isolated lung metastasis

Primary research

Identification of long noncoding RNA RP11-89K21.1 and RP11-357H14.17 as prognostic signature of endometrial carcinoma via integrated bioinformatics analysis

Primary research

XIST lost induces ovarian cancer stem cells to acquire taxol resistance via a KMT2C-dependent way

Primary research

MicroRNA-214-3p inhibits the stem-like properties of lung squamous cell cancer by targeting YAP1

Primary research

MicroRNA-585 inhibits human glioma cell proliferation by directly targeting MDM2
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits